Delivery Order SPE2DB20D6037-SPE2DB24FTXH6

Award Date 9/27/24
Potential Completion Date 9/30/24
Potential Value $15K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $39,371.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of TREMFYA 100 MG/ML INJECTORML, a specialized pharmaceutical product, with a completion date of February 13, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order valued at $11,587.21. The award was made by the Defense Logistics Agency (DLA) under the Medical Supply Chain program to provide a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) as a delivery order under the SPE2DB Indefinite Delivery Contract (IDC) valued at $499,999,999 and valid through November 2026. The contract provides the DLA with a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order valued at $82,417.09. The contract, awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain division, is part of a larger indefinite delivery contract (IDC) with the DLA valued at up to $499,999,999. This IDC, which runs through December 31, 2025, allows the DLA to issue delivery orders for a comprehensive range of...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $2,923.36 firm fixed-price delivery order contract is for the supply of a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This award is part of a larger indefinite delivery contract...
This is a federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The award, with a ceiling value of $26,681.01, is for the delivery of various pharmaceutical products and medical supplies to support the recurring medical needs of military health facilities globally. The contract has a firm fixed-price delivery order and runs through April 16, 2024. This award...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order valued at $1,040.04. The contract was awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain division to supply a variety of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. The contract is not set-aside and has an ultimate...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order with a ceiling value of $35,228.94. The award was made by the Defense Logistics Agency (DLA) under the SPE2DB program, an indefinite delivery contract (IDC) valued up to $499,999,999 that runs through December 31, 2025. This IDC allows the DLA to issue delivery orders for a comprehensive range of pharmaceutical items, including common...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The contract, valued at $12,934.05, is for the delivery of a range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $18,526.83 under a larger indefinite delivery contract (IDC) with the Defense Logistics Agency (DLA) worth up to $499,999,999. The contract, which runs through December 31, 2025, is for the supply of a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical...
  • SPE2DB20D6037
    Indefinite Delivery Contract
  • SPE2DB20D6037-SPE2DB24FTXH6
    Delivery Order

This federal contract award, valued at $14,876.32, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The award is a firm fixed-price delivery order under the DLA's SPE2DB program, a single-award indefinite delivery contract (IDC) valued up to $499,999,999 that runs through December 31, 2025. Under this IDC, DMS Pharmaceutical Group provides a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables, to support the recurring medical supply needs of Department of Defense (DoD) healthcare facilities worldwide. The contract award is not set aside and covers the delivery of TREMFYA 100 mg/mL syringes, with a period of performance ending on September 30, 2024.

Generated 12/27/24, 9:12 AM